Elacestrant is an oral selective estrogen receptor degrader (SERD) indicated for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer with estrogen receptor alpha (ESR1) mutations. It functions as an estrogen receptor antagonist that binds to ERα and induces its degradation via the proteasome pathway, thereby inhibiting 17β-estradiol-mediated cell proliferation. Elacestrant demonstrates antitumor activity in both in vitro and in vivo models of ER+/HER2- breast cancer, including those resistant to fulvestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, as well as models harboring ESR1 mutations.